Background {#Sec1}
==========

In 2016, the World Health Organization (WHO) released elimination targets including an 80% reduction in new hepatitis C virus (HCV) infections and 65% reduction in HCV related mortality by 2030 \[[@CR1]\]. Indeed, there is considerable optimism HCV elimination is possible due to the advent of highly-effective, short duration, tolerable, all-oral HCV direct-acting antiviral therapies (DAAs) which can cure \> 90% of HCV monoinfected and HIV/HCV coinfected individuals alike, and which modeling studies indicate could prevent onwards transmission at a population level \[[@CR2]--[@CR12]\]. In response, numerous countries are developing or have developed plans to scale-up HCV treatment to achieve these elimination targets, and focused efforts at microelimination (elimination among targeted populations, settings, or limited geographical areas) among key populations such as people living with HIV (PLWH) have been developed. For example, clinical societies such as the British HIV Association have set HCV microelimination targets among HIV+ populations \[[@CR13], [@CR14]\], yet how to achieve microelimination is unclear. Indeed, recent studies highlighting observations of dramatic reductions in HCV incidence observed among HIV+ men who have sex with men (MSM) in the Netherlands alongside widespread DAA scale up \[[@CR15]\], combined with modeling studies indicating HCV elimination may be achievable among PLWH in France \[[@CR16]\], have fuelled optimism that microelimination among PLWH is achievable.

In 2015, Spain developed a National Strategy for HCV treatment and instituted widespread scale-up of HCV DAA therapies for individuals coinfected with HIV and HCV, the vast majority (\> 85%) with a reported history of injecting drug use, and the remainder MSM or unknown \[[@CR17]\]. PWID are the main group at risk for HCV infection in Spain, and the main group at risk for prevalent and incident HIV/HCV coinfection \[[@CR17]--[@CR19]\]. In 2015, a multicentre prospective observational cohort of HIV-infected patients with chronic HCV infection from 21 reference centers in Andalusia, Spain was established (HERACLES cohort). From 2015 to 2017, the HERACLES cohort was used to assess HCV treatment uptake and outcomes among HIV/HCV coinfected patients, since implementation of the Spanish National Strategy \[[@CR17], [@CR20]\]. As such, it provided important data with which to examine the potential impact of this treatment scale-up on HCV incidence among PLWH and the broader population.

Numerous theoretical epidemic modeling studies have explored the potential of HCV treatment for prevention in a range of global settings \[[@CR5]--[@CR8]\]. Despite several studies modeling HIV and HCV coinfection transmission among PWID \[[@CR21]--[@CR23]\], and HCV prevention among HIV-positive MSM \[[@CR24]--[@CR27]\], to our knowledge no published study has explored how to achieve microelimination within HIV+ individuals when the vast majority of new infections are among PWID. One study examined elimination among HIV+ individuals in France \[[@CR16]\], but did not incorporate full transmission dynamics from HIV-negative PWID, which could contribute substantially to infection/reinfection among HIV-infected individuals with ongoing injecting risk. Additionally, that study did not examine the impact of treatment scale-up to coinfected individuals on the broader HCV epidemic among PWID.

We use dynamic epidemic modeling to assess the population impact of HCV treatment scale-up to HIV-infected individuals on HCV incidence among PLWH and the broader population, and implications for achieving the WHO HCV elimination target of 80% reduction in incidence by 2030, using Andalusia, Spain as a case study.

Methods {#Sec2}
=======

Mathematical model {#Sec3}
------------------

A deterministic dynamic coinfection model was developed, and calibrated to Andalusia, Spain. The model was stratified by PWID and MSM risk groups (Fig. [1](#Fig1){ref-type="fig"}a). The PWID component included dynamic HCV transmission from the HCV-monoinfected population, and therefore a joint HIV and HCV transmission model was developed to simulate the transmission of HIV and HCV due to injecting (HIV and HCV) and sexual risk (only HIV) among PWID (Fig. [1](#Fig1){ref-type="fig"}b). The joint model incorporated infection with HIV only (uninfected, HIV-infected undiagnosed, HIV-infected diagnosed and in care), HCV only (uninfected, HCV chronically infected (RNA+), HCV chronically infected treatment failure), and HIV/HCV coinfection (stratified by the above characteristics). Due to observed differences in HIV and HCV prevalence by injecting status and duration, the model was additionally stratified by history of injection drug use with PWID who initiated injecting \< 10 years ago (j = 1), PWID who initiated injecting \> 10 years ago (j = 2) and ex-PWID (j = 3). The model is open, such that PWID continually enter the "PWID who initiated \<10yrs ago" compartment, and leave all stages through cessation of injecting or death. We assume HCV transmission only occurs among PWID; ex-PWID do not contribute to transmission. HIV injecting-related transmission occurs among PWID, and HIV sexual transmission occurs between all PWID and ex-PWID. As 97% of HIV-infected individuals who are diagnosed and in care are on HIV antiretroviral therapy (ART) in Spain \[[@CR28]\], and 97% of HIV/HCV coinfected individuals in Andalusia are on ART \[[@CR17]\] we make the simplifying assumption that all individuals who are HIV diagnosed and in care are on ART. We assumed that HIV-infected PWID can become diagnosed and in care, where they are at decreased probability of injecting and sexual HIV transmission compared to the undiagnosed stage due to receipt of ART. As per clinical practice in Spain, we assume that all individuals who are diagnosed with HIV will be tested for HCV. Finally, the model incorporates biological interactions between HCV and HIV infection, such that HIV-infection reduces the probability of HCV spontaneous clearance (Table [1](#Tab1){ref-type="table"}) \[[@CR2], [@CR32]\]. Additionally, we assumed HIV infection increases HCV transmissibility through elevated HCV viral loads if the individual is not on ART \[[@CR46], [@CR47], [@CR58], [@CR59]\]. As the vast majority of newly diagnosed and prevalent HIV/HCV coinfections are among PWID, we utilize a simplified model of HCV/HIV coinfection among MSM, stratifying the model by HCV treatment status (treatment naïve, failed treatment, achieved SVR and are at risk of reinfection) and incorporated a fixed incidence of infection and reinfection. As there are currently no restrictions on retreatment after reinfection in Spain, we allow retreatment for individuals who are reinfected after successful treatment. Individuals who fail treatment (do not attain sustained viral response SVR) are not retreated. Fig. 1Model schematics showing (**a**) stratification by population and (**b**) HIV and HCV transmission and treatment stages for the PWID component. PWID: people who inject drugs. MSM: men who have sex with men. HCV: hepatitis C virus. SVR: sustained viral responseTable 1Model parameters and Sources**Calibration DataCalibrated parameterValue and Source**Number of diagnosed and in care HIV-infected and chronic HCV coinfected (HIV+/HCV+) in 20153075 as observed in the HERACLES cohort \[[@CR17]\], with 2669 \[range 2402--2936\] with a history of PWIDHCV chronic prevalence among PWID injecting for \< 10 years in 201045% \[sampled uniformly from 40 to 50%\]. Values from Folch et al. \[[@CR29]\], adjusted for weighted spontaneous clearance given HIV coinfection prevalence and spontaneous clearance rates by HIV-status in the below table.HCV chronic prevalence among PWID injecting for \> 10 years in 201060% \[sampled uniformly from 55 to 65%\] Values taken from Folch et al. \[[@CR29]\], adjusted for weighted spontaneous clearance given HIV coinfection prevalence and spontaneous clearance rates by HIV-status in the below table.HIV prevalence among PWID injecting for \<10 years, in 201020% \[sampled uniformly from 10 to 30%\] Values from Folch et al. \[[@CR29]\]HIV prevalence among PWID injecting for \> 10 years in 201040% \[sampled uniformly 30--50%\]. Values from Folch et al. \[[@CR29]\]HCV chronic prevalence among HIV+ ever PWID in 201554% \[sampled uniformly 50--58%\] \[[@CR18]\]Proportion of HIV+/HCV+ diagnosed individuals who are current PWID in 201514% \[sampled uniformly 10--18%\] as observed in the HERACLES cohort \[[@CR17]\]Proportion HIV+/HCV+ diagnosed ever PWID who had previously failed HCV treatment in 201532% \[sampled uniformly 30--34%\] as observed in the HERACLES cohort \[[@CR17]\]**General ParametersParameter DefinitionSymbolSampled Value and 95% IntervalSampling DistributionSource**Sustained HCV viral response, monoinfected on DAAs1- *f*~*md*~0.9\[[@CR2]\]Sustained HCV viral response, coinfected on DAAs1- *f*~*cd*~0.948HERACULES cohortSustained HCV viral response, monoinfected pre-DAAs1- *f*~*mpd*~0.52 (0.45--0.60)Uniform \[0.45--0.60\]Pooled SVR weighted by genotype and genotype distribution \[[@CR30], [@CR31]\].Sustained HCV viral response, coinfected pre-DAAs1- *f*~*cpd*~0.30 (0.20.-0.39)Uniform \[0.20--0.40\]Pooled SVR weighted by genotype and genotype distribution \[[@CR30], [@CR32]\].Excess death rate due to mono-infection with HIV untreated per yearμ~uHIV~0.097 (0.09--0.10)Uniform \[1/9.6--1/11.5\]\[[@CR33]\]Decreased mortality hazard ratio for HIV on ARTμ~HIV~0.26 (0.20--0.32)Uniform \[1/5--1/3\]\[[@CR34], [@CR35]\]Excess death rate due to chronic HCV mono-infection per yearμ~HCV~0.00169 (0.0016--0.00181)Uniform \[0.00154--0.00183\]\[[@CR36]\]Relative risk of death due to chronic HCV for HIV/HCV coinfection not on HIV treatment compared to HCV monoinfectionRR~\_co_noART~2.58 (1.70--3.99)Lognormal, from distribution 2.5 (95%CI 1.8--3.4)\[[@CR36], [@CR37]\]Excess death rate due to HCV for HIV-HCV co-infection with no HIV treatment per yearμ~HCVuHIV~0.0042 (0.0039--0.0046)Uniform \[0.0038--0.0046\]\[[@CR36], [@CR37]\]Relative risk of death due to chronic HCV for HIV/HCV coinfection on HIV treatment compared to HIV/HCV coinfection no HIV treatmentRR~\_coART~0.68\[[@CR36], [@CR37]\]Excess death rate due to HIV for HIV-HCV co-infection with no HIV treatment per yearμ~uHIVHCV~0.0005 (0.00041--0.00066)Uniform \[0.0004--0.00069\]\[[@CR36]\]PWID parametersInflow of new PWID per year*θ*Deaths replaced, rate is halved in 2011. See text for discussion.Population size of active PWID in 20107,500 (5,000-10,000)Uniform \[5,000-10,000\]8.4 million Andalusia population in 2010, 92% \> age 15, and a PWID prevalence among adults of 0.1% (national estimate) \[[@CR38], [@CR39]\],HCV treatment rate among PWID who are HIV- or HIV+ and undiagnosed (%/year)*r*, *r*~*hu*~0.99% (0.54--1.44%)Uniform\[0.5--1.5%\]Assumed similar to estimates worldwide \[[@CR40]\]HCV treatment rate among HIV+ diagnosed individuals prior to 2015 (%/year)*r*~*hd*~CalibratedCalibrated to fit HERACLES data on proportion previously failed treatment in 2015HCV treatment rate among HIV+ diagnosed individuals from 2015 to 2020 (%/year)*r*~*hd*~33%HERACLES cohort (*unpublished data from 2015 to 2017)*Average duration of injecting until final cessation (years)1/μ~cd~15.1 (6.8--24.4)Uniform\[5--25\]Uncertain, so vary widely \[[@CR41], [@CR42]\]Background mortality rate per year among PWIDμ0.0179Average life expectancy in Spain to 80.7 (WHO life table), and average age of injecting initiation age of 25 \[[@CR43]\]Overdose mortality rate among PWID per yearμ~IDU~0.0062 (0.005--0.007)Uniform \[0.0053--0.0070\]\[[@CR44]\]Relative risk of HIV transmission through sex for those on ARTRR~HIVs~0.107 (0.03--0.198)Lognormal \[95% CI 0.01--0.27\]\[[@CR45]\]Relative risk of HIV transmission through injecting for those on ARTRR~HIVi~0.50 (0.27--0.72)Uniform\[0.25--0.75\]Limited data. One modeling study in Vancouver estimated 44% efficacy for preventing injecting transmission \[[@CR5]\] but uncertainty was wide.Relative risk of HCV transmission if HIV positive undiagnosed (off ART) compared to HIV negativeRR~HCV_ifHIVpos~2 (1.2--2.8)Uniform \[1--3\]\[[@CR46], [@CR47]\]Annual probability of HIV transmission through sex during the latent untreated stage of infectionβ~HIVs~ = 1/6\* β~HCV~\[[@CR21]\]Proportion spontaneous HCV clearance among HIV negatives∆~n~0.25 (0.22--0.29)Uniform \[0.22--0.29\]\[[@CR48]\]Relative risk of spontaneous clearance among HIV positives compared to HIV negativesRR^sponclearHIVpos^0.68 (0.39--0.90)Lognormal \[0.46--1.0\]\[[@CR49]\]MSM parametersNumber of HIV/HCV coinfected and diagnosed MSM in 2015406HERACLES cohort (*unpublished)*Number of newly HIV/HCV coinfected and diagnosed MSM each yearCalculatedBased on multiplying the number of HIV-infected MSM in 2010 by the proportion of HIV+ MSM who are diagnosed, by the primary HCV incidence among HIV-infected MSM.Number of HIV-infected MSM in 2010*θ*~*MSM*~16,281 (9,018--23,526)Uniform\[8,646-23,913\]\[[@CR50]--[@CR52]\]Based on multiplying the male population over 15 years of age by the prevalence of MSM, and the prevalence of HIV-infected MSM in 2010Proportion of HIV+ MSM who are diagnosed0.761 (0.751--0.771)Uniform\[0.75--0.772\]\[[@CR53]\]Primary HCV incidence among HIV-infected MSM (per 100 person-years)1.17 (0.75--1.16)Uniform\[0.73--1.61\]\[[@CR54]\]See [supplement](#MOESM1){ref-type="media"} for details.HCV reinfection incidence among HIV+ MSM (per 100 person-years)Γ7.07 (3.87--10.27)Uniform\[3.7--10.44\]\[[@CR55]\]Background (non HIV or HCV) mortality rate among HIV/HCV-diagnosed MSM (per year)μ~MSM~0.026Average life expectancy in Spain of 80.7 \[[@CR56]\], and average age at HIV/HCV diagnosis of 43 \[[@CR57]\].

Model setting and data {#Sec4}
----------------------

The model was parameterized by and calibrated to data from Andalusia, Spain. Information on the diagnosed HIV/HCV coinfected population in Andalusia was obtained from the HERACLES cohort ([clinicaltrial.gov](http://clinicaltrial.gov): NCT02511496), a prospective cohort of 3075 HIV-infected individuals with chronic HCV infection from 21 reference hospitals set up in March 2015, and followed for 24 months \[[@CR17]\]. Of them, 2669 patients (86.7%) had a reported previous or current history of injecting drug use. These individuals were drawn from 19 centers treating 15,556 HIV-infected patients, which represent 99.3% of the HIV-infected patients in the Andalusia Health care system. Information such as age, route of HIV and HCV transmission, genotype, history of HCV therapy, and opiate substitution therapy (OST) use was collected. Individuals in the cohort were followed-up every 3 months, with the main objective of evaluating the current status and follow-up of chronic HCV infection in patients coinfected with HIV in Andalusia. Information from the cohort was used to obtain the following data for the model: the number of HIV individuals diagnosed with chronic HCV and with a history of injecting drugs in 2015, the proportion of HIV/HCV diagnosed individuals who are PWID, the proportion of HIV-infected ever PWID with chronic HCV infection who previously failed treatment in 2015, the HCV treatment uptake rate among HIV/HCV coinfected individuals with a history of injecting from 2015 to 2017.

The model was calibrated to the following data from the HERACLES cohort: 3075 diagnosed HIV+/HCV+ coinfected individuals in 2015. Of these, 2669 had a history of injecting drug use, among whom an estimated 14% were current PWID (defined as receipt of OST or current injecting risk. Thirty-two percent were treatment experienced and who had failed previously therapy. Additionally, the model was calibrated to the following epidemiological data from Spain: chronic HCV prevalence of 45 and 60% among PWID who initiated injecting \< 10 years ago and \> 10 years ago, respectively in 2010 \[[@CR29]\], HIV prevalence of 20 and 40% among PWID who initiated injecting \< 10 years ago and \> 10 years ago, respectively in 2010 \[[@CR29]\], chronic HCV prevalence among HIV+ ever PWID (PWID and ex-PWID) of 54% in 2015 \[[@CR18]\], and HCV reinfection incidence among HIV+ MSM of 5.93/100 person-years \[[@CR55]\]. Due to a lack of available data, we used global pooled estimates of HCV primary incidence among HIV+ MSM (see Table [1](#Tab1){ref-type="table"} and [supplement](#MOESM1){ref-type="media"} for details) \[[@CR18], [@CR54], [@CR55]\].

Several data sources coincide in indicating a reduction in the numbers of people newly initiating injecting drug use over the past decade in Andalusia and across Spain more broadly. First, data from OST admissions in Andalusia indicates a sharp drop among people with a history of heroin use in 2011 (from approximately 4000--4600 per year across 2005--2010 and then declining to 2400--2800 per year from 2011 to 2015 (via the Indicador Admisiones a Tratamiento 2015). At the same time, national surveillance data indicates a drop in the contribution of PWID to new HIV infections between 2004 and 05 and 2010--11, which could be attributable to population changes such as a reduction in people newly initiating injecting drug use leading to fewer newly initiated PWID at risk instead of lower transmission risk \[[@CR28], [@CR60]\]. Given these data, we incorporated a reduction in the entry rate of new PWID starting in 2011 (by 50% based on a halving of entrants to OST in Andalusia starting in 2011 onwards).

Given uncertainty in the data underlying the model's parameterization and calibration, we sample parameters and generate multiple model fits. We sampled most parameters from underlying distributions (Table [1](#Tab1){ref-type="table"}) using Latin Hybercube Sampling a total of 500 times. The model was calibrated to the sampled epidemiological data detailed above (HCV and HIV prevalence among PWID by duration of injecting, HCV prevalence among HIV+ ever-PWID, number diagnosed HIV/HCV coinfected MSM and ever-PWID, proportion diagnosed HIV/HCV coinfected ever-PWID who are current PWID, and proportion of diagnosed HIV/HCV coinfected ever-PWID who had previously failed HCV treatment). The model was calibrated using an optimization solver with multiple start points minimizing the least squares (MATLAB lsqnonlin solver using the MultiStart function), and selecting fits which lay within the uncertainty range for HCV and HIV prevalence among PWID from the data. This resulted in 134 selected model fits which were used for the full model simulations.

HCV treatment {#Sec5}
-------------

### Pre DAA treatment rates (prior to 2015) {#Sec6}

We assumed HCV treatment started in 2004, at a low rate of 1% among HCV moninfected PWID consistent with other global settings \[[@CR61]\]. We calibrated the HCV treatment rate among diagnosed HIV/HCV coinfected individuals to fit the HERACLES data on proportion who had previously failed treatment in 2015 (no difference was observed between risk groups).

Observed DAA scale-up (from 2015) {#Sec7}
---------------------------------

Consistent with observations in the HERACLES cohort and more broadly among HIV-infected cohorts in Spain, we model a scale-up of HCV DAA therapy to HIV-diagnosed individuals from 2015 onwards. In the first 24 months of DAA availability from 2015, 63% of HIV/HCV coinfected individuals within the HERACLES cohort in Andalusia were treated (*unpublished data from 2015 to 2017*). The proportion of individuals treated was significantly lower among PWID at 55% (defined as on OST or with a history of injecting \< 10 years) compared to ex-PWID or MSM 70%. Given these data, we incorporate a HCV treatment rate of 33%/year among diagnosed HIV/HCV coinfected PWID, ex-PWID and MSM from 2015 onwards. Observed SVR rates of 94.8% among the HERACULES cohort were used. We assume treatment rates among HCV monoinfected PWID remained stable at pre-2015 values.

### HCV Treatment Scale-Up Scenarios from 2020 {#Sec8}

We model the impact on HCV incidence and chronic prevalence among PLWH and overall until 2030 with the following scenarios: **Status quo:** Continuing current treatment rates (33%/year among diagnosed HIV/HCV coinfected individuals from 2015 as observed in the HERACLES cohort from 2015 to 2017)**Coinfected scale-up from 2020:** 100% screening and treatment of coinfected individuals**All PWID scale-up from 2020:** As in \[[@CR2]\] plus HCV treatment of HCV moninfected PWID of 10%/yr**No scale-up from 2015** (counterfactual scenario of continuation of historic treatment rates of 10.5% among diagnosed HIV/HCV coinfected individuals)

### Univariate sensitivity analyses {#Sec9}

Multiple univariate sensitivity analyses were performed to test the sensitivity of results to parameter assumptions on the relative reduction in the annual number of newly diagnosed HIV/HCV coinfections in scenario 3 (all PWID scale-up from 2020). Due to uncertainty in future SVR rates, we evaluate the impact of lower DAA SVR (85 and 90% vs. 95% at baseline). Additionally, because there is uncertainty in the PWID entry rate, and whether the observed declines in first time entrants to OST reflect true population reductions in new initiates to injecting, we also evaluate a scenario where the rate of injecting initiation did not decline in 2010.

Results {#Sec10}
=======

Epidemic prior to DAA scale-up in 2015 {#Sec11}
--------------------------------------

The model fit well to the HIV and HCV calibration data (Supplementary Figure [1](#MOESM1){ref-type="media"} ), producing model runs, which represent the range of uncertainty in our data. The annual number of newly diagnosed HIV/HCV coinfections (defined as new HCV infections among HIV-diagnosed as well as new diagnoses of HIV among HCV-infected individuals, some who may have acquired their HCV prior to their HIV infection) was projected to be 200 infections (2.5--97.5% interval 139--299) in 2015, the majority (84%) among those with a history of injecting drug use. Among PWID, we project that HCV chronic prevalence was increasing among PWID in Andalusia due to a reduction in the number of PWID initiating injecting, leading to an aging cohort with higher burden of disease (Supplementary Figure [3](#MOESM1){ref-type="media"}). In 2015, an estimated mean of 46% of all prevalent HCV infections and an estimated mean of 12% of incident HCV infections among PWID were among HIV+ PWID.

Modeled impact of observed DAA scale-up since 2015 {#Sec12}
--------------------------------------------------

Observed scale-up of DAAs to HIV-diagnosed individuals since 2015 (from an estimated 10.5%/year to 33%/year as observed in the HERACLES cohort) likely reduced the number of diagnosed coinfected individuals by 12% (mean 3289 in 2015 to 1324 in 2019 Fig. [2](#Fig2){ref-type="fig"}a). However, the number of newly diagnosed HIV/HCV coinfections was projected to increase, from a mean of 200 in 2015 to 221 in 2019 (Fig. [2](#Fig2){ref-type="fig"}b) due to reinfection after successful treatment among those with ongoing risk. Fig. 2Mean model projections of the (**a**) number of HIV/HCV diagnosed individuals (**b**) number of new HIV/HCV diagnosed individuals with observed scaled-up DAA treatment rates from 2015 in Andalusia with various treatment scale-up scenarios

Continuing current DAA treatment rates among HIV-diagnosed individuals could dramatically reduce the number of prevalent diagnosed coinfected individuals (mean 76% relative reduction (95%I: 75--76) from 2015 to 2030, Fig. [2](#Fig2){ref-type="fig"}a, black line), moderately reduce the number of newly diagnosed HIV/HCV coinfections (mean 12% relative reduction (95%I: 10--15) from 2015 to 2030, Fig. [2](#Fig2){ref-type="fig"}b, black line), and would moderately increase the number of new HCV infections (diagnosed and undiagnosed) among PLWH (mean − 12% relative reduction (95%I: − 38 - 36) 2015--2030). When considering the impact on the broader HCV epidemic, the model projects continuing current rates would reduce the number of new HCV infections by a relative 29% (95%I: 19--37%) by 2030.

Among PWID, (Fig. [3](#Fig3){ref-type="fig"}), the scale-up was projected to marginally reduce both chronic HCV prevalence (mean relative reduction of 5% \[95%I: 1--7%\]) and incidence rates among PWID (mean relative reduction of 9% \[95%I: − 0.09 to 10%\]) from 2015 to 2019. Negative lower bounds correspond to scenarios where HCV chronic prevalence slightly increased from 2015 to 2019 due to background population dynamics. Without scale-up of treatment from 2015, the model projects that HCV incidence and prevalence in 2019 would have been higher (Fig. [3](#Fig3){ref-type="fig"}, dashed grey line). Fig. 3Mean model projections of the (**a**) number of chronic HCV infections (**b**) number of new chronic HCV infections with observed scaled-up DAA treatment rates from 2015 in Andalusia with various treatment scale-up scenarios

Modeled future impact of further scale-up of DAA treatment among HIV/HCV coinfected individuals {#Sec13}
-----------------------------------------------------------------------------------------------

If all coinfected individuals were diagnosed and treated annually from 2020, this could lead to an 85% (95%I: 83--86%) relative reduction from 2015 in number of diagnosed coinfected individuals by 2030. However, this would only reduce the annual number of new diagnosed coinfections by 8% (95%I: 7--16%) by 2030. (Fig. [2](#Fig2){ref-type="fig"}b, blue line).

If treatment were scaled-up to both PLWH as well as the broader PWID population with HCV monoinfection, then greater impact could be achieved. For example, if all coinfected individuals were diagnosed and treated annually from 2020, and in addition 10% of HCV monoinfected PWID were treated annually, then this could lead to a reduction in the annual number of new diagnosed coinfections by 22% (95%I: 19--32%) (Fig. [2](#Fig2){ref-type="fig"}b, green line), an increase in the number of new HCV infections by a relative 31% (95%I: 26--38%) among HIV+ populations (Supplementary Figure [6](#MOESM1){ref-type="media"}), and a reduction in the number of new HCV infections overall by a relative 36% (95%I: 35--41%) 2015--2030 (Fig. [4](#Fig4){ref-type="fig"}b, green line). Fig. 4Mean model projections for HCV chronic prevalence and incidence among people who inject drugs (**a**, **c**) and HIV+ people who inject drugs (**b**, **d**) in Andalusia, Spain with various treatment scenarios and 95% Sustained Virologic Response

Sensitivity analyses {#Sec14}
--------------------

Sensitivity analyses on our scenario with all PLWH and 10% of HCV monoinfected PWID were treated annually from 2020 showed that the model projections were highly sensitive to assumptions regarding PWID population dynamics. If the PWID population remained constant and did not decline starting in 2010, it would result in a mean increase in the number newly diagnosed coinfections among PWID and MSM (from 313 in 2015 to 384 in 2030). This compares to a reduction in the number newly diagnosed coinfections among PWID and MSM at baseline (Fig. [5](#Fig5){ref-type="fig"}). Little differences were observed when reducing DAA SVR rates to 90% or 85%, which resulted in slightly fewer newly diagnosed coinfections due to less opportunity for reinfection (Fig. [5](#Fig5){ref-type="fig"}). Fig. 5Mean model projections of the number of new HIV/HCV diagnosed individuals with all PLWH and 10% of HCV monoinfected PWID treated annually from 2020 among PWID and MSM between 2015 and 2030, comparing scenarios with varying sustained virologic response rates (solid lines) and a stable PWID population size (dashed line)

Discussion {#Sec15}
==========

Our analysis indicates that recent scale-up of HCV treatment to HIV/HCV coinfected individuals in Spain since 2015 may have had an impact on reducing the number of existing and newly diagnosed HCV infections among PLWH, but will not achieve microelimination among HIV/HCV coinfected individuals, or elimination more broadly. Further scale-up to diagnose and treat all PLWH each year could halve HCV incidence among PWID by 2030, but will likely not achieve the WHO elimination goal of 80% reduction in HCV incidence by 2030. Elimination or microelimination efforts should focus on HCV screening, linkage to care, treatment, and harm reduction provision among both coinfected individuals and the broader population at continued risk of transmission, such as PWID.

Strengths and weaknesses {#Sec16}
------------------------

To our knowledge, this is one of the first analyses to evaluate the impact of HCV treatment programs prioritizing PLWH on achieving the WHO elimination targets among PLWH and the broader population. One previous study conducted in France modeled the HCV epidemic among HIV-positive patients from all risk groups, finding that elimination was feasible among these groups \[[@CR16]\]. However, their study did not incorporate dynamic HCV transmission from the monoinfected HCV population, assuming a low fixed incidence among HIV-positive PWID. Due to a combination of biological, behavioral, and historical factors \[[@CR62]--[@CR64]\], the majority of PWID acquire HCV within the first few years of injecting initiation and prior to their HIV infection \[[@CR65]\]. Hence, the incidence of acute HCV among HIV+ PWID is low and may underestimate the true risk of reinfection in many settings like Andalusia. Indeed, we found that the risk of reinfection and continued incidence of new HIV/HCV coinfections among PWID important drivers of the epidemic. A strength of our model, thus, is the use of a dynamic HIV and HCV coinfection model incorporating injecting transmission of HCV from outside the HIV/HCV coinfected population. Our work supports previous modeling analyses that scale-up of HCV treatment to PWID could have a substantial prevention benefit and reduce incidence at a population level \[[@CR5]--[@CR9]\], but highlights the limitations of focusing elimination efforts only on subsets of risk groups (such as HIV+ PWID). Additionally, our modeling findings are similar to analyses focusing on HCV transmission among MSM \[[@CR24], [@CR25]\], which have found that substantial HCV transmission from HIV-uninfected or undiagnosed MSM may hamper HCV elimination efforts if treatment is focused only on HIV-diagnosed individuals.

As a modeling study, our analysis has a number of limitations. Firstly, we are limited by uncertainty in underlying epidemiological data. To account for this uncertainty, we sampled the prevalence from wide uncertainty bounds and ran numerous simulations which fit to different epidemic scenarios and propagated this uncertainty in future projections. Despite this uncertainty, all our projections supported our general finding that HCV elimination among PWID is unlikely to be achieved through current treatment rates, and that it requires targeting both HIV/HCV-coinfected and HCV-monoinfected individuals. We additionally lacked data on HCV retreatment rates among HIV-infected PWID who were successfully treated and then reinfected, and assumed that reinfection were eligible for retreatment. We believe this is a reasonable assumption, as firstly, guidelines do not mention retreatment restrictions, and secondly, accelerated disease progression among HIV/HCV coinfected individuals provides a strong indication for treatment/retreatment. However, if retreatment were not allowed, we would expect to achieve less impact.

Second, our analysis focuses on the impact of HCV treatment among HIV-infected individuals on burden among HIV+ MSM and PWID, but only includes treatment as prevention benefits among PWID. Most incident HCV infections in Spain are among PWID, and the majority of HIV/HCV coinfected individuals having a history of injecting drug use \[[@CR17]\]. Within the HERACULES cohort in Andalusia, only 3% of HIV/HCV coinfected individuals were MSM \[[@CR17]\]. Although traditionally MSM have been the focus of many studies of acute HCV among HIV-infected individuals, this is because PWID usually acquire HCV early on in their injecting careers and prior to their HIV infection \[[@CR54]\]. As such, our study primarily focused on treatment as prevention benefits among PWID who contribute to the vast majority of overall HCV incidence. Additionally, we assume transmission epidemics between PWID and MSM populations are distinct and non-overlapping, based on phylogenetic analyses in Europe indicating that HCV transmission among HIV+ MSM occurs separately from PWID, \[[@CR66], [@CR67]\]. However, some overlap has been noted among the PWID and MSM populations in Australia \[[@CR68]\]. Further, we used country-level (for Spain) HCV reinfection incidence data from HIV+ MSM and pooled HCV primary incidence data from HIV+ MSM because Andalusia-specific data were unavailable. Therefore, molecular and epidemiological data on HCV transmission specific to MSM in Andalusia would strengthen this analysis and allow for quantification of the additional benefit on MSM transmission, and potential transmission between populations.

Third, our study focuses only on MSM and PWID populations, as this comprised \< 91% of reported risks in the Andalusia cohort \[[@CR17]\]. Less than 1% of individuals reported risk due to being blood donors, and the remainder had none of the above reported risks. Due to the very small number of blood-donor derived infections, we neglected this group as the risk of ongoing incidence or reinfection due to this transmission mode is negligible. As the risk of HCV transmission through heterosexual transmission is low \[[@CR69], [@CR70]\], we believe it is possible that these individuals may not have reported PWID or MSM risk. The inclusion of these individuals in our model as PWID or MSM would not affect our results in terms of relative reductions in incidence (which is our primary outcome), although it would mean that the absolute numbers in each category were slightly higher than we report.

Fourth, we model a scenario of 100% screening and treatment of PWID from 2018 to highlight the potential maximum impact of a comprehensive HCV treatment strategy, but acknowledge that this type of scale-up would be ambitious. In reality, there are a number of barriers to the implementation of such a comprehensive diagnosis and treatment program. Enhanced diagnosis rates among PWID would likely require expanded provision of testing in both harm reduction services and outreach to identify harder to reach individuals, using multiple testing modalities such as point of care diagnosis and noninvasive testing. After diagnosis, strong systems ensuring effective linkage to care are required, particularly among PWID who may experience periods of homelessness and incarceration which may disrupt these linkages. Indeed, incarceration has been associated with increased HIV and HCV risk among PWID globally, and hence could pose a challenge to HCV prevention, yet at the same time could be an opportunity for HCV diagnosis and treatment in the DAA era. Finally, the cost of current DAA therapies is still high, which could act as a barrier to immediate universal scale-up of HCV treatment. As Spain has recently relaxed the HCV restrictions regarding therapy and allowing for universal access, it remains to be seen whether this translates into substantial uptake among the broader PWID population.

Fifth, we do not account for the impact of scaled-up harm reduction on the HCV and HIV epidemics among PWID. A recent Cochrane systematic review and meta-analysis found that opiate substitution therapy and high coverage needle and syringe programs are effective at preventing HCV, by roughly 50% (for OST), 76% (for high coverage NSP in Europe) and 74% in combination \[[@CR71]\]. Modeling studies have shown the substantial impact that combination harm reduction can have on HCV epidemics among PWID \[[@CR72]\], and future work should examine the potential impact of combination treatment and harm reduction among HIV+ populations.

Lastly, we note that our dynamic model predicts epidemic dynamics using epidemiological data from 2010 to 2017, which is the most recent data available for Andalusia. More recent data are needed, as they would allow for model validation and confirmation that treatment scale-up is leading to observed reductions in HCV incidence or chronic prevalence, and to confirm whether Andalusia is on track for HCV elimination.

Conclusions {#Sec17}
===========

In conclusion, microelimination of HCV among HIV+ PWID in Spain requires a focus on elimination of HCV transmission among PWID, both moninfected and coinfected alike. Eliminating HCV from HIV-positive populations will require efforts to prevent HCV infection among PWID prior to their HIV infection, and therefore elimination efforts should focus on combination prevention among the broader PWID population.
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**Additional file 1: Figure S1.** Mean model projections of the (A) number of HIV/HCV diagnosed active PWID (B) number of new HIV/HCV diagnosed active PWID, (C) number of chronic HCV infections among active PWID, and (D) number of new chronic HCV infections among active PWID with observed scaled-up DAA treatment rates from 2015 in Andalusia with various treatment scale-up scenarios. **Figure S2.** Mean model projections of the number of new. HIV/HCV diagnosed MSM with observed scaled-up DAA treatment rates. From 2015 in Andalusia with various treatment scale-up scenarios. **Figure S3.** Model projections (mean and 95% intervals) for HCV chronic prevalence and incidence among people who inject drugs (A,C) and HIV+ people who inject drugs (B,D) in Andalusia, Spain with observed scaled-up DAA treatment rates from 2015. Black line indicates mean projection, grey lines indicate 2.5--97.5% interval projections. **Figure S4.** Comparison of the model projected trends in HCV chronic prevalence among HIV+ individuals with a history of injecting drug use against the data. Model projections shown as solid line (black the mean projection, and gray lines the 2.5--97.5% interval projections). Calibration data sampling bounds (minimum and maximum) shown in red. **Figure S5.** Comparison of the model projected trends in HIV and HCV prevalence against the data. HIV prevalence (A,B) and HCV chronic prevalence (C,D) shown among people who inject drugs by injecting duration (\> 10 years and \< 10 years). Model projections shown as solid lines (black the mean projection, and gray lines the 2.5--97.5% interval projections). Calibration data sampling bounds (minimum and maximum) shown in red. **Figure S6.** Mean model projections of the number of new HCV infections among HIV+ MSM and PWID in Andalusia, Spain if all coinfected individuals were diagnosed and treated annually from 2020, and in addition 10% of HCV monoinfected PWID were treated annually.

HCV

:   Hepatitis C virus

PLWH

:   People living with HIV

PWID

:   People who inject drugs

MSM

:   Men who have sex with men

DAAs

:   Direct-acting antiviral therapies

SVR

:   Sustained viral response

OST

:   Opiate substitution therapy
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